No Data
Syren Biotech: third quarter report 2024
Selon Biotechnology (688163.SH): net income in the first three quarters was 62.9475 million yuan, a year-on-year increase of 23.92%.
Gelonghui October 25th news: Selon Bio (688163.SH) released its third-quarter report, with revenue of 0.173 billion yuan for the first three quarters, a year-on-year increase of 4.31%, net income of 62.9475 million yuan, a year-on-year increase of 23.92%, non-net profit of 50.32 million yuan, a year-on-year increase of 30.93%, and basic earnings per share of 0.58 yuan.
Cellon (688163.SH) released its performance for the first three quarters, with a net income of 62.9475 million yuan, a year-on-year increase of 23.92%.
Cellon (688163.SH) released the third quarter report for the first three quarters of 2024, during which the company achieved revenue...
Shanghai Serum Bio-Technology Co., Ltd.'s (SHSE:688163) 44% Price Boost Is Out Of Tune With Earnings
Salubris Bio (688163.SH) plans to distribute a dividend of 0.12 yuan per share on September 12th.
Sailun Biology (688163.SH) announced that the company plans to distribute interim dividends for the first half of 2024: cash dividends per share...
Syren Biotech: 2024 Semi-Annual Report
Is Shanghai Serum Bio-Technology Co., Ltd.'s (SHSE:688163) Stock On A Downtrend As A Result Of Its Poor Financials?No Data
No Data
